The combination of anti-programmed death receptor 1 (PD-1), or its ligand (PD-L1), and chemotherapy has recently gained attention in patients with advanced non-small cell lung cancer (NSCLC). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.